The latest London South East Webinar takes place on July 6. Come and hear CEO’s from Orosur Mining, Caledonia Mining, Glantus Holdings and Tekcapital speak. Please register here

Less Ads, More Data, More Tools Register for FREE

UK to give under 40s alternative to AstraZeneca vaccine

Fri, 7th May 2021 09:49

(Sharecast News) - The UK government decided on Friday to offer people under 40 an alternative to the AstraZeneca Covid-19 vaccine, reported Bloomberg.
The decision followed a recommendation from the Joint Committee on Vaccination and Immunisation and will be implemented just as the inoculation program is set to reach under 40s.

People under 40 will be offered vaccines by Pfizer-BioNtech and Moderna which, the only other shots that have clinched approval in the UK.

The offer comes after officials linked "extreme rare" incidents of blood clotting to the AstraZeneca shot in younger people.

A total of 79 cases had been recorded thus far, including 19 deaths out of the more than 20.0m doses administered.

The company said when the link was made that it was "working to understand the individual cases, epidemiology and possible mechanisms that could explain these extremely rare events."

Related Shares

More News

AstraZeneca, MSD prostate cancer drug gets China green light

(Sharecast News) - AstraZeneca and MSD's Lynparza prostate cancer drug has been granted conditional approval in China after a successful phase three trial, the companies said on Thursday.

Today 07:34

Wednesday broker round-up

(Sharecast News) - Hunting: JP Morgan upgrades overweight with a target price of 290p.

23 Jun 21 13:04

Delta plus variant reclassified as 'variant of concern', experts sanguine for now

(Sharecast News) - India's Health Ministry has upgraded a new variant of Covid-19 dubbed Delta plus to a "variant of concern".

23 Jun 21 10:47

AstraZeneca's 'Orpathys' gets conditional approval in China

(Sharecast News) - AstraZeneca announced on Wednesday that 'Orpathys', or savolitinib, has been granted conditional approval in China to treat patients with non-small cell lung cancer (NSCLC), with MET exon 14 skipping alterations who have progressed following prior systemic therapy or were unable to receive chemotherapy.

23 Jun 21 07:33

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.